Litigation Details for In Re: Zetia (Ezetimibe) Antitrust Litigation (E.D. Va. 2018)
✉ Email this page to a colleague
In Re: Zetia (Ezetimibe) Antitrust Litigation (E.D. Va. 2018)
| Docket | ⤷ Subscribe | Date Filed | 2018-06-15 |
| Court | District Court, E.D. Virginia | Date Terminated | 2023-12-14 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Rebecca Beach Smith |
| Jury Demand | Plaintiff | Referred To | Douglas E. Miller |
| Patents | 7,030,106; 7,612,058; RE37,721; RE42,461 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In Re: Zetia (Ezetimibe) Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe , ⤷ Subscribe , and ⤷ Subscribe .
Details for In Re: Zetia (Ezetimibe) Antitrust Litigation (E.D. Va. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-09-11 | 1113 | claimed three patents associated with Zetia, Patent Nos. 5,846,966, RE7721 and 7,030,106, and Glenmark… for all three patents.17 Merck sued Glenmark for infringement of the RE7721 patent on March 23, 2007.18…has received final approval from the FDA.9 Patents and several types of exclusivities may prevent …prevent final approval of an ANDA.10 Where patents or other exclusivity barriers are in place, but the FDA…final approval will not be granted until the patent or exclusivity issues have been resolved.12 One | External link to document | |
| 2018-09-05 | 128 | Amended Complaint | as U.S. Patent No. 7,030,106. The ’106 patent was Merck’s first sterol non-absorption patent. It has…azetidinone patents include the ’365 patent, the ’115 patent, the ’966 patent, the RE’721 patent, and the…three patents for these discoveries (one reissued as U.S. Patent No. RE37,721 (the “RE’721 patent”)).… 5. Patents are not bulletproof. 43. Patents are not bulletproof. Patents are routinely… A patent is also invalid or unenforceable when a later acquired patent is not patentably distinct | External link to document |
| 2018-09-13 | 130 | Amended Complaint | as U.S. Patent No. 7,030,106. The ’106 patent was Merck’s first sterol non-absorption patent. It has…azetidinone patents include the ’365 patent, the ’115 patent, the ’966 patent, the RE’721 patent, and the… Patents are not bulletproof. 48. Patents are not bulletproof. Patents are routinely… A patent is also invalid or unenforceable when a later acquired patent is not patentably distinct…azetidinone patent application – issued as U.S. Patent No. 5,631,365. The ’365 patent was the first-issued | External link to document |
| 2022-02-09 | 1498 | .S. Patent Application No. 10/136,968 issued as U.S. Patent No. 7,030,106 (the “’106” patent), titled…two patents to protect its Vytorin monopoly: U.S. Patent No. RE 37,721 (the “RE ’721” patent) 11 …11 and U.S. Patent No. 5,846,966 (the “’966” patent). The RE ’721 patent purportedly covered Zetia…“mistakes” in the patents — first, the RE ’721 patent, and then U.S. Reissue Patent No. RE 42,461… ’721 patent or any members of the RE ’721 patent family. Consequently, the RE ’721 patent constituted | External link to document | |
| 2022-02-09 | 1499 | .S. Patent Application No. 10/136,968 issued as U.S. Patent No. 7,030,106 (the “’106” patent), titled…two patents to protect its Vytorin monopoly: U.S. Patent No. RE 37,721 (the “RE ’721” patent) 8 and… and U.S. Patent No. 5,846,966 (the “’966” patent). The RE ’721 patent purportedly covered Zetia …“mistakes” in the patents — first, the RE ’721 patent, and then U.S. Reissue Patent No. RE 42,461… ’721 patent or any members of the RE ’721 patent family. Consequently, the RE ’721 patent constituted | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
